News

For the year 2008, GAAP net income was $108.7 million, or $0.96 per diluted share, compared to $78 million, or $0.69 per diluted share, in 2007. Mindray reported

For the year ended December 31, 2008, net income was $7.52 million, or $0.34 per diluted share, compared to $3.26 million, or $0.19 per diluted share, for the

Revenues for the first quarter ended January 31, 2009 were $87.4 million, up 5% from $82.9 million for the first quarter ended January 31, 2008. Steve Dubin, CEO

Exelixis said that the increase in the net loss for the quarter was primarily due to the inclusion in 2007 of the gain of $18.1 million associated with

Arkema, a manufacturer of chemical products, reported for the fourth quarter of 2008 a net loss of €72m, in comparison with a net profit of €18m for the

“We are very pleased to welcome Al to our Supervisory Board,” commented Bernhard Sixt, president and chief executive officer of Agendia. “As we continue to expand our U.S.

John LaMattina, PhD, has agreed to give his presentation “Dispelling Pharma R&D Myths” at the luncheon. Dr. LaMattina is now retired from a 30-year career with Pfizer. Before

US-based biopharmaceutical company TissueGene has announced that its South Korean licensing partner Kolon Life Science has received regulatory allowance from the Korea Food and Drug Administration to initiate

In late February, I. Lanier Avant, the Majority staff director of the committee, stated a bill to reauthorise the Chemical Facility Anti- Terrorism Standards (CFATS) and add Inherently